Back to Peptides

TB-500 (Ac-LKKTETQ)

Moderate Research

Thymosin Beta-4 Active Fragment | Healing Peptide

Dose 2-2.5mg per injection
Frequency 2x weekly (e.g., Monday and Thursday)
Cycle 4-6 weeks loading phase
Storage Reconstituted: 2-8°C refrigerated

TB-500 (Ac-LKKTETQ) is a synthetic derivative of thymosin beta-4 consisting of the N-terminal acetylated 17-23 amino acid fragment. This sequence represents the active site within thymosin beta-4 responsible for actin binding, cell migration, and wound healing. Research shows it promotes endothelial cell differentiation, angiogenesis, keratinocyte migration, collagen deposition, and decreases inflammation. The acetylation protects against N-terminal degradation while maintaining biological activity.

Mechanism of Action

TB-500 contains the LKKTETQ sequence which is the actin-binding motif of full-length thymosin beta-4. This fragment shares many properties of the parent protein regarding cell proliferation, differentiation, and migration. It promotes angiogenesis by upregulating VEGF expression and enhancing endothelial cell sprouting. The peptide undergoes serial cleavage at the C-terminus during metabolism, while the N-terminal acetylation provides protection from degradation.

Key Benefits

  • Promotes wound healing
  • Enhances cell migration
  • Supports angiogenesis (new blood vessel formation)
  • Reduces inflammation
  • Promotes keratinocyte migration
  • Supports collagen deposition
  • Enhances tissue repair
  • Active region of thymosin beta-4
Molecular Weight
844 Da
Chain Length
7 amino acids
Type
Acetylated heptapeptide
Amino Acid Sequence
One-letter: ?LKKTETQ
H₂N
H
? 1
O ‖ C
N
L 2
O ‖ C
N
K 3
O ‖ C
N
K 4
O ‖ C
N
T 5
O ‖ C
N
E 6
O ‖ C
N
T 7
O ‖ C
N
Q 8
COOH
Ac
1

Ac

Position 1

Leu
2

Leucine

Position 2

Lys
3

Lysine

Position 3

Lys
4

Lysine

Position 4

Thr
5

Threonine

Position 5

Glu
6

Glutamic Acid

Position 6

Thr
7

Threonine

Position 7

Gln
8

Glutamine

Position 8

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Tissue Repair

  • Wound Healing

    Promotes dermal wound healing through the active LKKTETQ sequence.

  • Tissue Regeneration

    Supports tissue repair comparable to full thymosin beta-4 in research.

  • Skin Repair

    Promotes keratinocyte migration and collagen deposition.

Vascular Support

  • Angiogenesis

    Promotes endothelial cell differentiation and new blood vessel formation.

Anti-Inflammatory

  • Inflammation Reduction

    Decreases inflammatory responses in damaged tissues.

TB-500 is typically administered via subcutaneous injection. The N-terminal acetylation provides stability and protection from degradation. Not authorized for medicinal use; research peptide only.

GoalDoseFrequencyRoute
Loading phase2-2.5 mg2x weekly for 4-6 weeksSubQ
Maintenance2 mgWeekly or bi-weeklySubQ

Reconstitution Instructions

Materials Needed:
  • Bacteriostatic water
  • Insulin syringes
  • Alcohol swabs
  • Peptide vial
  • Sterile work surface
  1. 1 Clean work area and hands thoroughly
  2. 2 Calculate required BAC water volume
  3. 3 Draw BAC water into syringe
  4. 4 Inject slowly down vial side
  5. 5 Gently swirl until dissolved (never shake)
  6. 6 Store reconstituted solution refrigerated
BPC-157

Commonly combined for enhanced healing effects through different mechanisms.

synergistic
Thymosin Beta-4

TB-500 is the active fragment; combining may be redundant.

compatible
GHK-Cu

Both support wound healing and tissue repair through different pathways.

synergistic
IGF-1 LR3

Different mechanisms; may complement for tissue growth.

compatible
Days 1-7

Initial wound healing acceleration

Week 1-2

Enhanced cell migration and angiogenesis

Week 2-4

Visible tissue repair improvements

Week 4-6

Full healing benefits; transition to maintenance

Common Side Effects

  • Injection site reactions
  • Mild fatigue
  • Head rush (reported)

Stop Signs - Discontinue if:

  • Allergic reactions
  • Unusual swelling or inflammation

Contraindications

  • Not authorized for medicinal use
  • Active cancer (theoretical concern)
  • Pregnancy or breastfeeding
  • Prohibited by WADA in sports

Good Signs

  • White lyophilized powder
  • Clear solution after reconstitution
  • High purity (>98%)
  • Intact vacuum seal

Warning Signs

  • Not authorized for human use
  • Research chemical only

Bad Signs

  • Discoloration
  • Cloudy solution
  • Particulates visible
  • Synthesis and Characterization of N-terminal Acetylated 17-23 Fragment of Thymosin Beta-4
    Drug Testing and Analysis (2012)

    TB-500 contains Ac-LKKTETQ, the active site responsible for actin binding and wound healing.

  • Doping Control Analysis of TB-500
    Journal of Chromatography B (2012)

    TB-500 is a synthetic version of the active region of thymosin beta-4.

  • TB-500 Metabolism and Wound Healing
    Journal of Chromatography B (2024)

    TB-500 undergoes serial cleavage at C-terminus; acetylation protects N-terminus.

  • Investigation of TB-500 Metabolism
    WADA (2018)

    Characterized human metabolism of TB-500 using liver microsomes and S9 fraction.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.